Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Adherium Reports Fourth Straight Quarter of Record RPM Revenue
Adherium logs fourth straight quarter of record RPM revenue, $479k to June, with 3,831 activated patients and a 68,000-patient pipeline as growth accelerates.
Latest Stories — SECTOR DESK
Imricor Launches US Operations with Cardiac Imaging System at Rady Children’s Hospital in San Diego
Imricor launches US ops with NorthStar MRI-guided cardiac mapping at Rady Children's after FDA paediatric clearance, enabling radiation-free procedures.
Adherium Outlines Commercial Progress and Value-Based Care Strategy
Adherium shifts to recurring respiratory care as RPM revenue surges 9.4x; 5,300 devices shipped, 2,600+ active patients, US$55/mo, targeting 10,000 by year-end.
Resonance Health Improves Cash Position as Clinical Trial Pipeline Expands
Resonance Health boosts FY26 cash to net $2.3m, receipts $14.3m; pipeline over $12m as MRI liver fibrosis trial recruitment completes.
Clinuvel Looking to Access Greater Market Share with Corporate Restructure and US Relocation
Clinuvel relocates HQ to US, trims up to 20% staff, refocuses on US pipeline; Nasdaq listing aims to boost US investor access and partnerships.
Proteomics International Appoints Healius Exclusive Australian Distributor for Promarker Blood Tests
Proteomics inks exclusive Australian distributor deal with Healius for Promarker blood tests, enabling nationwide rollout by 2027; revenue not yet estimable.
Radiopharm Theranostics Reports Positive Results from RAD204 and RAD101 Trials
Radiopharm Theranostics reports durable partial response for RAD204 in Phase 1; RAD101 Phase 2b brain mets shows 93% MRI-PET concordance, 86% sensitivity.
Lumos Diagnostics Expands FebriDx Rollout Across Priority US Urgent Care Accounts
Lumos Diagnostics expands FebriDx rollout to 430 US urgent care sites across top accounts, targeting 2.6 million ARI visits annually—rapid expansion under way.
Optiscan Imaging Advances Head and Neck Cancer Study Ahead of Schedule
Optiscan Imaging pushes Stage 2 of head and neck cancer live-imaging study ahead of schedule, accelerating clinical validation and potential FDA submissions.
LTR Pharma Executes US Commercialisation Agreement with Shed DTC Platform
LTR Pharma inks US ROXUS deal with Shed; targets 150k units in year one via Mavrox telehealth—fast-acting 10-min onset.
Dimerix Expands Kidney Pipeline With Phase 2-Ready Acquisition
Dimerix expands kidney pipeline with DMX-652 acquisition; Phase 2-ready AKI therapy targets US$3.5b market, upfront US$5m plus up to US$292m milestones.
Argenica Therapeutics Reports ARG-007 Neuroprotection in Concussion Study
Argenica's ARG-007 delivers durable neuroprotection after repeat mild TBI in a concussion model, hinting at a disease-modifying therapy from a single dose.